Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Gross Margin (2022 - 2025)

BioXcel Therapeutics has reported Gross Margin over the past 4 years, most recently at 87.5% for Q4 2025.

  • Quarterly results put Gross Margin at 87.5% for Q4 2025, up 21482.0% from a year ago — trailing twelve months through Dec 2025 was 74.45% (up 6907.0% YoY), and the annual figure for FY2025 was 74.45%, up 6903.0%.
  • Gross Margin for Q4 2025 was 87.5% at BioXcel Therapeutics, down from 88.78% in the prior quarter.
  • Over the last five years, Gross Margin for BTAI hit a ceiling of 96.22% in Q4 2022 and a floor of 446.73% in Q3 2024.
  • Median Gross Margin over the past 4 years was 88.14% (2025), compared with a mean of 8.82%.
  • Biggest five-year swings in Gross Margin: crashed -39658bps in 2024 and later surged 53550bps in 2025.
  • BioXcel Therapeutics' Gross Margin stood at 96.22% in 2022, then crashed by -193bps to 89.89% in 2023, then crashed by -42bps to 127.32% in 2024, then skyrocketed by 169bps to 87.5% in 2025.
  • The last three reported values for Gross Margin were 87.5% (Q4 2025), 88.78% (Q3 2025), and 10.83% (Q2 2025) per Business Quant data.